A new study on the effect of the anti-obesity drug rimonabant on liver function in obese rats found that it reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles.The results of this study appear in Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience [click link for full article]